ArticleDiscover oncology2025
Deciphering the causal effects of plasma metabolomics and lipids on breast cancer risk: a Mendelian randomization analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer, a complex disease influenced by metabolic and lipid profiles, requires a deeper understanding of causal relationships between dietary preferences, plasma metabolites, and cancer risk. This study employed Mendelian randomization (MR) to explore causal links between dietary preferences, plasma metabolites, and ER-negative/ER-positive breast cancer risk, alongside underlying mechanisms. The genome-wide association study (GWAS) data regarding dietary preferences, plasma metabolites, and plasma lipids were obtained from the GWAS database, with sample sizes of 161,625, 8,299, and 7,174 respectively. Meanwhile, the GWAS data related to breast cancer and its subtypes (ER + breast cancer and ER- breast cancer) were sourced from the IEU Open GWAS project, with sample sizes of 228,951, 175,475, and 127,442 respectively. Reverse MR and mediation analyses were conducted to assess bidirectional relationships and mediating roles of plasma biomarkers. The analysis revealed significant causal effects of dietary preferences and plasma metabolites on breast cancer risk. Mediation analysis identified key pathways: curry preference (β = -0.015, 95% CI [-0.029, -0.001], P = 0.034) reduced breast cancer risk through increased phosphatidylcholine levels, while tomato preference (β = 0.021, 95% CI [0.002, 0.041], P = 0.031) increased risk via the serine to α-tocopherol ratio. Additionally, bitter beer preference (β = -0.012, 95% CI [-0.024, -0.000], P = 0.038) was inversely associated with ER-negative breast cancer risk, mediated by specific metabolites, whereas sweetened tea preference (β = 0.015, 95% CI [0.030, 0.059], P = 0.026) positively correlated with ER-negative risk through distinct plasma biomarkers. These findings underscore the importance of dietary factors and plasma metabolites in modulating breast cancer risk across subtypes. The study highlights potential mediation mechanisms, offering insights into the complex interplay between diet, metabolism, and cancer. These results advance our understanding of breast cancer etiology and may inform personalized prevention and treatment strategies, emphasizing the role of targeted dietary interventions and biomarker-driven approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.